EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunogenicity and Protection of mRNA Vaccine Encoding Spike Protein of SARS-CoV-2 Omicron-XEC Subvariant

Xiaoqing Guan iD, Hansam Cho, Qian Liu, Shengnan Qian, Lanying Du

International Journal of Molecular Sciences · 09.05.2026 · 27 (10) · 4218

DOI: 10.3390/ijms27104218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 09.05.2026. Verfasst von Xiaoqing Guan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, SARS-CoV-2, COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The surface spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a key target for the development of Coronavirus Disease 2019 (COVID-19) vaccines. Nevertheless, the mutations in the S protein, particularly in its receptor-binding domain region, have resulted in a reduced or complete loss of immunogenicity and/or protective efficacy in early vaccines against the Omicron variant and subvariants. Accordingly, continuous efforts are required to develop effective vaccines against multiple Omicron subvariants to reduce current and future threats. In this study, we designed an mRNA vaccine targeting the S protein of a recent Omicron-XEC subvariant (XEC-S-mRNA) and assessed its immunogenicity, including its broad neutralizing activity, and its protective efficacy against multiple Omicron subvariants. Our results demonstrated that the lipid nanoparticle-formulated mRNA vaccine formed an appropriate particle size with strong stability and successful antigen expression. It elicited durable cellular immune responses and broad neutralizing antibodies against multiple early and recent Omicron subvariants, thereby cross-protecting transgenic mice from challenge with a heterologous Omicron strain (KP.3). Moreover, the vaccine-induced neutralizing antibodies alone were sufficient to prevent Omicron-KP.3 infection. Overall, this study shows promise for further development of the candidate vaccine against current and future Omicron infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spike Glycoprotein, CoronavirusSARS-CoV-2COVID-19 VaccinesCOVID-19Immunogenicity, VaccineAnimalsAntibodies, NeutralizingMiceAntibodies, ViralmRNA VaccinesHumansFemaleMice, TransgenicVaccines, SyntheticRNA, MessengerNanoparticlesMice, Inbred BALB C

Stichwörter der Autor:innen

COVID-19Omicron variantSARS-CoV-2coronaviruscross-neutralizing activitymRNA vaccineprotective efficacyspike protein

Substanzen

Spike Glycoprotein, CoronavirusCOVID-19 Vaccinesspike protein, SARS-CoV-2Antibodies, NeutralizingAntibodies, ViralmRNA VaccinesVaccines, SyntheticRNA, Messenger

Autor:innen und Institutionen

  • Institute for Biomedical Sciences, Georgia State University, Atlanta, GA 30303, USA.

ORCID-Profile: Xiaoqing Guan

Zitieren

APA

Guan, X., Cho, H., Liu, Q., Qian, S., & Du, L. (2026). Immunogenicity and Protection of mRNA Vaccine Encoding Spike Protein of SARS-CoV-2 Omicron-XEC Subvariant. International Journal of Molecular Sciences, 27(10), 4218. https://doi.org/10.3390/ijms27104218

Vancouver

Guan X, Cho H, Liu Q, Qian S, Du L. Immunogenicity and Protection of mRNA Vaccine Encoding Spike Protein of SARS-CoV-2 Omicron-XEC Subvariant. International Journal of Molecular Sciences. 2026;27(10):4218. doi:10.3390/ijms27104218

BibTeX
@article{Guan2026,
  author = {Guan, Xiaoqing and Cho, Hansam and Liu, Qian and Qian, Shengnan and Du, Lanying},
  title = {Immunogenicity and Protection of mRNA Vaccine Encoding Spike Protein of SARS-CoV-2 Omicron-XEC Subvariant},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {10},
  pages = {4218},
  doi = {10.3390/ijms27104218}
}
Kostenlos starten →